Researchers discover new mechanism of gene regulation

February 26, 2014, Fox Chase Cancer Center

In the cells of humans and other organisms, only a subset of genes are active at any given time, depending largely on the stage of life and the particular duties of the cell. Cells use different molecular mechanisms to orchestrate the activation and deactivation of genes as needed. One central mechanism is an intricate DNA packaging system that either shields genes from activation or exposes them for use.

In this system, the DNA strand, with its genes, is coiled around molecules known as histones, which themselves are assembled into larger entities called nucleosomes. Together, nucleosomes and DNA form chromatin, which is the primary substance of chromosomes. This DNA-packaging system is vital for managing development and maintaining health. When it goes awry, cancer can be the result.

In a study published in Molecular Cell this month, Alexei V. Tulin, PhD, Associate Professor at Fox Chase Cancer Center, and colleagues reported that chemical modification of one type of histone—called H2Av—leads to substantial changes in nucleosome shape. As a consequence, a previously hidden portion of the nucleosome becomes exposed. This newly exposed portion interacts with and activates an enzyme called PARP1. Upon activation, PARP1 assembles long branching molecules of Poly(ADP-ribose), which appear to open the DNA packaging around the site of the PARP1 activation, exposing specific genes for activation.

"Currently, the nucleosome is often portrayed as a stable, inert structure, or a tiny ball," Tulin says. "We found that the nucleosome is actually a quite dynamic structure. When we modified one histone, we changed the whole nucleosome."

In addition to reevaluating how histones control gene activation, the study also reports a new mechanism of PARP1 regulation. Many standard cancer treatments, including chemotherapy drugs and radiation therapy, damage the DNA of rapidly dividing cancer cells. However, the effectiveness of these treatments is limited. Research has suggested that standard therapies combined with drugs that inhibit PARP1 can kill cancer cells, but clinical trials testing PARP1 inhibitors in cancer patients have produced disappointing outcomes. "I believe that to a large extent the previous setbacks were caused by a general misconception of the role of PARP1 in living cells and the mechanisms of PARP1 regulation," Tulin says. "Now that we know this mechanism of PARP1 regulation, we can design approaches to inhibit this protein in an effective way to better treat cancer."

The ability of PARP1 to control cellular processes is regulated by nucleosomes—the basic unit of DNA packaging, consisting of a segment of DNA wound in sequence around eight histone protein cores, similar to a thread wrapped around a spool. Histones undergo different chemical modifications that play an important role in regulating the activity of genes. Through this mechanism, histones control the ability of PARP1 to activate genes and repair DNA damage.

"This mechanism of PARP1 regulation by histones is still very new," Tulin says. "People believe that PARP1 is mainly activated through interactions with DNA, but we have found that the main pathway of PARP1 activation is through interactions with the nucleosome." In the new study, Tulin and his colleagues reevaluated how PARP1 is activated by changes in the nucleosome. They found that the addition of a phosphate group to a histone—called H2Av—triggered the entire nucleosome to change shape, exposing previously hidden parts of the that began to interact with and activate PARP1.

To follow up on these findings, Tulin and his team are now developing the next generation of PARP1 inhibitors. Designed to block the newly identified mechanism of PARP1 activation, these new inhibitors will specifically target PARP1, in contrast to the PARP1 inhibitors currently being tested in clinical trials.

"We expect that our targeted PARP1 inhibitors will be more effective at killing while protecting important molecular pathways in normal cells," Tulin says. "For this reason, we believe that the specific inhibitors we are designing hold great promise for cancer treatment."

Explore further: Cisplatin-resistant cancer cells sensitive to experimental anticancer drugs, PARP inhibitors

Related Stories

Cisplatin-resistant cancer cells sensitive to experimental anticancer drugs, PARP inhibitors

April 3, 2013
Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published ...

Cancer research unlocks 30-year genetic puzzle

June 12, 2012
(Medical Xpress) -- Scientists at the University of Sussex have solved a 30-year genetic puzzle that could help enhance treatment for certain types of “inherited” cancers.

Novel therapeutic targets identified for small cell lung cancer

September 6, 2012
Newly discovered molecular differences between small cell lung cancer and nonsmall cell lung cancer have revealed PARP1 and EZH2 as potential therapeutic targets for patients with small cell lung cancer, according to the ...

Recommended for you

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

Workouts may boost life span after breast cancer

January 22, 2018
(HealthDay)—Longer survival after breast cancer may be as simple as staying fit, new research shows.

Cancer patients who tell their life story find more peace, less depression

January 22, 2018
Fifteen years ago, University of Wisconsin–Madison researcher Meg Wise began interviewing cancer patients nearing the end of life about how they were living with their diagnosis. She was surprised to find that many asked ...

Single blood test screens for eight cancer types

January 18, 2018
Johns Hopkins Kimmel Cancer Center researchers developed a single blood test that screens for eight common cancer types and helps identify the location of the cancer.

Researchers find a way to 'starve' cancer

January 18, 2018
Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital ...

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

3 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

JVK
1 / 5 (1) Feb 27, 2014
Re: They found that the addition of a phosphate group to a histone—called H2Av—triggered the entire nucleosome to change shape, exposing previously hidden parts of the nucleosome that began to interact with and activate PARP1.

"In ecological terms, because of its important role in biological systems, phosphate is a highly sought after resource. Once used, it is often a limiting nutrient in environments, and its availability may govern the rate of growth of organisms."

http://en.wikiped...hosphate

That fact links ecological variation in the availability of phosphate and other nutrients to nutrient-dependent pheromone-controlled ecological adaptations in my model, which eliminates the nonsense of mutation-driven evolution as does this news release.

Nutrient-dependent/pheromone-controlled adaptive evolution: a model
http://www.socioa...53/27989

See also:
http://www.fccc.e...d/tulin/
Captain Stumpy
5 / 5 (1) Feb 27, 2014
That fact links ecological variation in the availability of phosphate and other nutrients to nutrient-dependent pheromone-controlled ecological adaptations in my model, which eliminates the nonsense of mutation-driven evolution as does this news release

@jvk
unfortunately for you... your MODEL causes MUTATIONS per the definition of MUTATION used by the geneticists, biologists and others in the field, therefore your links only SUPPORT evolution.
According to NIH
1- your model makes mutations
2- your argument predominantly is against single mutation speciation
3- You are arguing out of linguistic ignorance, inhibiting communication because you cannot understand the lexicon which governs your field/studies
JVK
1 / 5 (1) Feb 27, 2014
My MODEL can't cause anything, you idiot. It is a model of how cause and effect occur in the context of chemical ecology.

If you have experimental evidence that attests to the fact that phosphates or other nutrients cause mutations, provide the experimental evidence of cause and effect like I've been doing in a series of published works since 1995.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.